Search | Médecins Sans Frontières Access Campaign

Resources

Please use the filters below to refine your search

2420 results found

Goma, North Kivu province in the Democratic Republic of Congo (DRC), multi-antigen vaccination campaign.

Press release |

04 December 2023

Gavi Board must make catch-up vaccination a priority when allocating leftover COVAX money

With increasing number of vaccine-preventable disease outbreaks, urgently tackling glaring childhood immunisation shortfalls must be priority for Gavi and Board

Tags Vaccines Gavi, the Vaccine AllianceUNICEFWorld Health Organization

Technical brief |

24 November 2023

Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)

Q&A on access to HIV prevention drug CAB-LA

Tags HIV/AIDS HIV/AIDS cabotegravir ViiV

Between 2000-2021, the measles vaccine saved 56 million lives. In 2022, MSF provided 4 million measles vaccines in response to outbreaks.

Infographic

Vaccine infographics

Tags Tuberculosis tuberculosis

Technical brief |

15 November 2023

Access to TB Testing and Treatments: GeneXpert and Delamanid

The access barriers on lifesaving TB tools

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpert CepheidOtsuka

Dr Samsuddin Khan performs physical exam of Deepak Sabhash Shegar, a person living with DR-TB, at MSF DR-TB clinic, Chembur, Mumbai, India, 2022

Press release |

15 November 2023

Landmark Clinical Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options

endTB clinical trial offers new shortened drug regimens to treat multidrug-resistant TB

Tags Tuberculosis drug-resistant TBtuberculosis UNITAID

Issue brief |

15 November 2023

Addressing Antimicrobial Resistance Within Global Processes to Improve Pandemic Preparedness and Response

Ongoing PPR processes offer a promising pathway to complement and help implement pre-existing commitments on AMR

Tags Pandemic preparednessAntimicrobial resistance

MSF Medical Doctor Ramya, conducting physical examination of female DRTB patient during her follow-up visit to endTB clinic.

Press release |

14 November 2023

MSF warns governments are failing to test, treat and prevent TB in children

Governments must immediately implement latest WHO guidelines to stop children dying from TB

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpert World Health Organization

GeneXpert test technology has revolutionised the diagnosis of TB, allowing detection of the TB bacterium, and its resistance to drugs, in only two hours.

Press release |

07 November 2023

MSF responds to WHO’s annual global TB report: implores governments to use recent TB wins to beat back deadly infectious disease

Recent price reductions to WHO-recommended TB tests and treatment should enable more countries to make these vital medical tools available

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpertbedaquiline World Health Organization

Letter |

01 November 2023

Letter: Civil society calls on UK Prime Minister to ensure UK-India free trade agreement does not threaten access to affordable medicines

Open letter to UK Prime Minister on UK-India free trade agreement and access to medicines

Tags Intellectual property and trade free trade agreement

Different medications a person living with HIV may take every day. Upper-left picture shows a first line treatment. Upper-right is a second-line treatment for patients who do not respond to first-line treatment. Bottom-left is a third-line treatment for patients who do not respond to first- and second-line treatments. Bottom-right is a dolutegravir pill, a new molecule that suppresses viral load much faster than others.

Press release |

04 October 2023

In step to expand people's access to HIV treatment, Colombia plans to overcome patent barriers and issue a compulsory license

Colombia plans to issue compulsory license on HIV drug dolutegravir, expanding access

Tags HIV/AIDSIntellectual property and trade

January 2020 protest in front of the New York Stock Exchange, demanding J&J make bedaquiline more accessible for all people with drug-resistant TB.

Press release |

30 September 2023

MSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries

MSF welcomes Johnson & Johnson's intent not to enforce its patents on key TB drug bedaquiline, paving way for affordable generic versions

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson

Vaishnavi, 7, who lives with drug-resistant TB, interacts with MSF nurse Prachi, as her mother Vishaka holds her. Mumbai, India, 2022.

Press release |

22 September 2023

Commitments made in today's UN TB Declaration to scale up TB testing and treatment, and improve TB care for children, require immediate, concrete action

Governments must now turn words on paper into practice and take the necessary steps to save more lives of people with TB

Tags Tuberculosis drug-resistant TBtuberculosis

Fact sheet |

22 September 2023

Tuberculosis: Challenges and Breakthroughs

Despite being curable, why is TB the world’s deadliest infectious disease? What tools do we have to beat the disease?

Tags Tuberculosis drug-resistant TBtuberculosis

Letter |

21 September 2023

Ukraine: Open Letter: Urgent action by Johnson & Johnson needed to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

The Public Health Center of the Ministry of Ukraine (PHC) sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve equitable access to the lifesaving TB drug bedaquiline in ...

Tags Intellectual property and trade tuberculosis bedaquiline Johnson & Johnson Ukraine

Letter |

21 September 2023

Ukraine: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Civil society organisations, communities affected by tuberculosis (TB), and partner institutions in Ukraine sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve ...

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson Ukraine

Letter |

21 September 2023

Moldova: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Civil society organisations, communities affected by tuberculosis (TB), and partner institutions in Moldova sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve ...

Tags Intellectual property and trade tuberculosis bedaquiline Johnson & Johnson Republic of Moldova

Letter |

21 September 2023

Azerbaijan: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Civil society organisations, communities affected by tuberculosis (TB), and partner institutions in Azerbaijan sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve ...

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson Azerbaijan

GeneXpert test cartridge being used to test a sample of suspected TB in MSF’s lab at Bangassou Hospital, Central African Republic, 2017.

Press release |

19 September 2023

TB test price reduction by Cepheid and Danaher is an important step in the right direction

Cepheid and Danaher have just announced that they are reducing the price of the Xpert MTB/RIF test by 20% in high-TB-burden countries, from US$9.98 to $7.97 per test. This reduction is a significant step, considering the corporations ...

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpert Johnson & Johnson

Bottle of bedaquiline, Zhytomyr Regional TB Dispensary, Ukraine. In 2018, MSF started providing treatment for drug-resistant TB to people in Zhytomyr, Ukraine.

Photo credit: Oksana Parafeniuk

Blog |

15 September 2023

The long and winding road to ensure affordable access to a key TB drug

With the United Nations High-Level meeting just over the horizon, the TB community is ready to amplify the voices of people affected by TB around the world at this global forum, and demand the global attention and resources needed to beat this devastating yet curable disease.

Technical brief |

15 September 2023

From TRIPS to PPR: Addressing Intellectual Property Barriers on Lifesaving Medical Products

The ongoing PPR negotiations at WHO offer an opportunity to resolve the decades-long tension between IP and access

Tags Pandemic preparednessIntellectual property and trade coronavirus TRIPS WTO

Resources

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

Gavi Board must make catch-up vaccination a priority when allocating leftover COVAX money

Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)

Vaccine infographics

Access to TB Testing and Treatments: GeneXpert and Delamanid

Landmark Clinical Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options

Addressing Antimicrobial Resistance Within Global Processes to Improve Pandemic Preparedness and Response

MSF warns governments are failing to test, treat and prevent TB in children

MSF responds to WHO’s annual global TB report: implores governments to use recent TB wins to beat back deadly infectious disease

Letter: Civil society calls on UK Prime Minister to ensure UK-India free trade agreement does not threaten access to affordable medicines

In step to expand people's access to HIV treatment, Colombia plans to overcome patent barriers and issue a compulsory license

MSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries

Commitments made in today's UN TB Declaration to scale up TB testing and treatment, and improve TB care for children, require immediate, concrete action

Tuberculosis: Challenges and Breakthroughs

Ukraine: Open Letter: Urgent action by Johnson & Johnson needed to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Ukraine: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Moldova: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Azerbaijan: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

TB test price reduction by Cepheid and Danaher is an important step in the right direction

The long and winding road to ensure affordable access to a key TB drug

From TRIPS to PPR: Addressing Intellectual Property Barriers on Lifesaving Medical Products